What drug, zongertinib, received accelerated FDA approval in February 2026 for HER2-mutant non-small cell lung cancer?

The recent accelerated approval of zongertinib in February 2026 marks a significant milestone in the treatment of HER2-mutant non-small cell lung cancer (NSCLC). This targeted therapy, sold under the brand name Hernexeos, received its expanded accelerated approval from the U.S. Food and Drug Administration (FDA) for adults with unresectable or metastatic non-squamous NSCLC whose tumors possess specific HER2 (ERBB2) tyrosine kinase domain activating mutations, and importantly, who had not previously received systemic therapy for their advanced disease. This builds upon an earlier accelerated approval in August 2025 for patients who had already undergone prior systemic treatment.

HER2 mutations are a specific genetic alteration found in approximately 2-4% of non-small cell lung cancers, historically presenting a challenge for effective treatment. Zongertinib is a kinase inhibitor, meaning it works by specifically blocking the activity of the mutated HER2 protein, which can drive uncontrolled cancer cell growth. The FDA's decision was based on compelling data from the Beamion LUNG-1 trial, which demonstrated a notable objective response rate in patients. This accelerated approval pathway is utilized for drugs that address serious conditions and fulfill an unmet medical need, based on a surrogate endpoint, with the understanding that continued approval may depend on further verification of clinical benefit.

The introduction of zongertinib as the first targeted therapy for treatment-naïve patients with HER2-mutant advanced NSCLC represents a new standard of care, offering a crucial oral, once-daily treatment option. This advancement underscores the growing importance of comprehensive biomarker testing to identify specific genetic mutations in lung cancer, allowing for more precise and effective personalized medicine approaches.